natgillin/translations-raw huggingface dataset:
A beacon as claimed in claim 1, wherein said sunken seat is parallelepiped-shaped. A beacon as claimed in claim 1, wherein said sunken seat is closed by a flat plate positioned with its peripheral edges resting along an annular edge of the sunken seat to close said sunken seat in fluidtight manner. 
Baliza prema patentnom zahtjevu 1, naznačena time, da je navedeno upušteno sjedište (12a) zatvoreno ravnom pločom (22) smještenom svojim obodnim rubovima (22a) da počiva duž prstenastog ruba (20) upuštenog sjedišta, da na hermetički način zatvori navedeno upušteno sjedište.
a nucleic acid which is at least 95% identical to the nucleic acid of (a), (b) or (c) for use in a method of treatment or prevention of cancer characterized by expression of the tumor-associated antigen. 
(d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c) za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena koji je povezan sa tumorom.
A dispenser according to claim 1, wherein the junction member (41) sits atop the upper surface of the protrusion (18a), (18b). 
Dispenzer sukladno zahtjevu 1, naznačen time da spojni dio (41) leži povrh gornje površine izbočenja (184), (18b).
a first end for insertion into a stoma for diverting stomal effluent into the stoma extender before the effluent exits the stoma; 
prvi kraj (11) za umetanje u stomu radi preusmjeravanja stomalne otpadne tekućine u produžetak stome prije nego otpadna tekućina izađe iz stome;
A chemical entity or pharmaceutical composition as in claim 26, wherein said pharmaceutically acceptable salts are selected from succinate, hydrochloride, formate, maleate, acetate, fumarate, citrate, tartrate, sulfate, phosphate, malate, malonate and benzoate. 
Kemijski entitet ili farmaceutski pripravak prema patentnom zahtjevu 26, gdje su spomenute farmaceutski prihvatljive soli izabrane iz sukcinata, hidroklorida, formata, maleata, acetata, fumarata, citrata, tartrata, sulfata, fosfata, malata, malonata i benzoata.
composition, optionally presented in two or more parts for the preparation of a first colon cleansing solution by admixture with water; and 
A) pripravak, izborno prisutan u dva ili više dijelova namijenjenih pripravi prve otopine za čišćenje debelog crijeva dodavanjem vode; 1
The process according to claim 11, wherein the compound of Formula IIa is present at an amount of 0.025 molar. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što je navedeni spoj Formule II prisutan u količini od 0,025 mol.
insoluble whey protein particles having a particle size in the range of 1-10 µm, where the amount of said insoluble whey protein particles is in the range of 50-90% (w/w) relative to the total amount of protein. 
- netopljive čestice proteina sirutke veličine čestica u rasponu od 1-10 um, gdje je količina navedenih netopljivih čestica proteina sirutke u rasponu od 50-90 % (tež./tež.) u odnosu na ukupnu količinu proteina.
is chosen from hydrogen, alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl. 
R" je odabran između vodika, alkila, arila, alkilarila, supstituiranog alkila, supstituiranog arila, i supstituiranog alkilarila.
The method of claim 3 wherein the osmolality is increased by spiking said culture with a compound that increases said osmolality. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da je osmolalnost pojačana ubadanjem spomenute kulture komponentom koja pojačava navedenu osmolalnost.
A pharmaceutical composition according to claim 6 which is for administration by dry powder inhaler (DPI) or metered-dose inhaler (MDI). 
Farmaceutski pripravak prema zahtjevu 6 namijenjen za primjenu pomoću inhalatora za suhi prašak (DPI) ili inhalatora s odmjerenom dozom (MDI).
Netupitant for use according to claims 1-23, said use comprising treating nausea and vomiting in response to highly emetogenic chemotherapy during the acute phase, or in response to highly emetogenic chemotherapy during the delayed phase, or in response to moderately emetogenic chemotherapy during the acute phase, or in response to moderately emetogenic chemotherapy during the delayed phase. 
Netupitant za uporabu u skladu s patentnim zahtjevima 1-7, obuhvaća liječenje mučnine i povraćanja kao odgovora na vrlo emetogenu kemoterapiju za vrijeme akutne faze, ili kao odgovor na vrlo emetogenu kemoterapiju tijekom odgođene faze.
yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; 
(vi) prinosi su navdeni samo iz ilustrativnih razloga i ne predstavljaju nužno prinose koji se mogu dobiti temeljitim razvojem postupka; priprave su ponovljene ako je bilo potrebno više materijala;
The antibody of claim 3, wherein the antibody (a) neutralizes at least one member of each clade with a potency greater than that of the bNAbs b12, 2G1 2, 2F5 and 4E10 respectively, (b) does not bind monomeric gp120 or gp41 proteins of the HIV-I env gene or (c) binds with higher affinity to trimeric forms of the HIV-I Env expressed on a cell surface than to the monomeric gp120 or artificially trimerized gp140. 
Protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što protutijelo (a) neutralizira najmanje jedan član svakog klada s potentnošću većom od one za bNAbs b12, 2G12, 2F5 odnosno 4E10, (b) ne veže se na monomerne proteine #p120 ili gp41 iz HIV-1 env gena ili (c) veže se većim afinitetom prema trimernim oblicima HIV-1 Env koji se eksprimiraju na površini stanice nego prema monomernom gp120 ili gp140 trimeriziranom na umjetan način.
A method of treating Alzheimer's disease, mild cognitive impairment, or abnormal accumulation or deposition of beta-amyloid in the central nervous system in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to beta-amyloid, wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, respectively. 
Izolirano humano anti beta-amiloid antitijelo ili njegov antigen - vezujući fragment koji sadrže varijabilnu regiju teškog lanca (VH) i varijabilnu regiju lakog lanca (VL), naznačen time, da sadrži VH prvu regiju za određivanje komplementarnosti (VHCDR1) sa sekvencom aminokiseline SEQ ID NO:20, VHCDR2 sa sekvencom aminokiseline SEQ ID NO:21 i VHCDR3 sa sekvencom aminokiseline SEQ ID NO:22, i pri čemu VL sadrži VLCDR1 sa sekvencom aminokiseline SEQ ID NO:23, VHCDR2 sa sekvencom aminokiseline SEQ ID NO:24 i VHCDR3 sa sekvencom aminokiseline SEQ ID NO:25. Antitijelo ili njegov fragment u skladu s patentnim zahtjevom 1, naznačen time, da sadrži VH i VL sekvence aminokiselina onako kako je prikazano u SEQ ID NO:6 i SEQ ID NO:8.
In some embodiments, an anti-PD-1 antibody or antibody fragment may be combined with another therapeutic antibody useful for the treatment of cancer or infectious disease. 
Antitijelo ili fragment antitijela prema bilo kojem od patentnih zahtjeva 1 do 12 ili koje/koji se može dobiti pomoću postupka prema patentnom zahtjevu 18 za uporabu u liječenju kancera ili infekcije ili infektivne bolesti.
IL-18BP has been suggested as a therapeutic protein in a number of diseases and disorders, such as psoriasis, Crohn's Disease, rheumatoid arthritis, psoriatic arthritis, liver injury, sepsis, atherosclerosis, ischemic heart diseases, allergies, etc., e.g. disclosed in WO9909063, WO0107480, WO0162285, WO0185201, WO02060479, W002096456, W003080104, W002092008, W002101049, W003013577 . 
IL-18BP je predložen kao terapeutski protein u brojnim bolestima i poremećajima, primjerice psorijazi, Crohnovoj bolesti, reumatoidnom artritisu, psorijatičnim artritisu, pri ozljedama jetre, sepsi, aterosklerozi, ishemičnoj bolesti srca, alergijama itd., primjeri navedeni u WO9909063, WO0107480, WO0162285, WO0185201, WO02060479, WO02096456, WO03080104, WO02092008, WO02101049, WO03013577.
resistively heating the core by supplying it with electric current to reduce the viscosity of the surrounding filler material; and 
zagrijavanje jezgre (2) električnom strujom radi smanjivanja viskoznosti materijala za ispunu (7), koji se nalazi oko nje;
The volume of each of the discrete samples is user-selectable. In certain cases, the volume of each of the discrete samples is selected to be the same. 
Uređaj prema bilo kojem od gornjih zahtjeva, naznačen time da korisnik može birati volumen svakog od odvojenih uzoraka.
Wind system according to claim 5, characterised in that said first winches (24) have different surface roughness. 
Vjetreni sustav prema zahtjevu 5, naznačen time da spomenuta prva vitla (24) imaju površine različite hrapavosti.
In another aspect of the present invention, the present invention provides an apparatus for transmitting a signal, includes an information generator configured to generate a second pilot signal including a layer-1 information region for assigning layer-1 information, a frame builder (130) configured to arrange the generated second pilot signal in a preamble of a signal frame and arrange a physical layer pipe (PLP) in a specific region of the layer-1 information region, the PLP corresponding to a transport stream, a modulator configured to modulate the signal frame and a transmitting unit configured to transmit the modulated signal frame via at least one radio frequency (RF) channel. 
Uređaji za prijenos emitiranja okvira signala digitalne televizije, DTV, naznačen time, što se sastoji od: generatora informacije (1301) konfiguriranog za generiranje sloja-1 informacije, sloj-1 je fizički parametar za signalizaciju voda na fizičkom sloju, PLP, isporukom servisnog toka; okvira analizatora (130) konfiguriranog za izgradnju okvira signala koji se sastoji od korisnih sadržaja i uvoda, uvod obuhvaća prvi pilot signal koji prethodi drugom pilot signalu, drugi pilot signal uključujuće sloj-1 informacije u čemu PLP je uključen u korisne sadržaje i drugi pilot signal, i predajne jedinice (160A, 160r) konfigurirano za prijenos moduliranog okvira signala putem bar jedne radio frekvencije,RF, kanala.
B1, B2 and B3 are independently selected from the group consisting of CR2 and N; 
, B2 i B3 su neovisno odabrani iz skupine koju čine CR2 i N;
The compound as claimed in claim 8, wherein A is at least one member selected from the group of —H, —OH and —F. 
ormuia la poželjno gdje A je najmanje jedan član izabran iz grupe koju čine -H, -OH i -F; i poželjnije gdje A je -H ili -F.
In other embodiments compounds of the present invention cause less than about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 1% measurable flushing in an individual compared to an essentially equally effective dose of niacin. 
U ostalim oblicima spojevi prikazanog izuma uzrokuju manje od oko 80%, 75%, 65%, 60%, 55%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% ili 1% mjerljivog crvenila kod pojedinca u usporedbi s esencijalno isto učinkovitom dozom niacina.
A shelf-stable dairy mousse according to any one of claims 1 to 5wherein the shelf-stable dairy mousse has a dry content of from 25 wt % to 48 wt %. 
Mliječna pjena stabilna na sobnoj temperaturi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što mliječna pjena stabilna na sobnoj temperaturi ima sadržaj suhe tvari od 25%, težinski, do 48%, težinski.
The aqueous formulation of claim 8 comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/mL glycerol 85%. 
Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m-krezola i 20 mg/ml 85%-tnog glicerola.
Item 1. A compound represented by the formula (I) 
HR P20180483 T1 1. < Spoj, naznačen time, da je predstavljen formulom (I): gdje
A method of producing a vaccine against S. aureus infection comprising: 
Postupak za proizvodnju cjepiva protiv infekcije S. aureus naznačen time što sadrži:
An immunogenic composition according to any preceding claim wherein one or more or all carrier proteins is selected from the group consisting of DT, CRM197, TT, Fragment C, dPly, PhtA, PhyB, PhtD, PhtE, PhtDE OmpC, PorS and Haemophilus influenzae Protein D for use in the treatment or prevention of diseases caused by Streptococcus pneumoniae infection by serotype 19A strains. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je svaki saharid iz kapsule bakterije Streptococcus pneumoniae konjugiran s proteinskim nosačem kojeg se neovisno bira iz skupine koju čine tetanusni toksoid (TT), difterijski toksoid (DT), CRMI197, fragment C tetanusnog toksoida (TT), PhtD, fuzije PhtDE, detoksicirani pneumolizin i protein D. 12.
Process according to claim 15, wherein the content of aluminum sulfate is up to 5 wt.% based on the weight of the dry slurry. 
Postupak prema zahtjevu 13, naznačen time da sadržaj aluminijevog sulfata je sve do 5 tež.% bazirano na težini suhe suspenzije.
chlorinating a compound of Formula Vb: or a salt thereof, to form a compound of Formula Vc: or a salt thereof; and, 
klorinacija spoja formule Vb: ili njegove soli, u svrhu tvorbe spoja formule Vc:
The aqueous preparation according to claim 1, wherein the mineral material consists of ground calcium carbonate obtained from marble, limestone and/or chalk. The aqueous preparation according to claim 1, wherein the mineral material consists of precipitated calcium carbonate. The aqueous preparation according to claim 1, wherein the source of the lithium ions is a water soluble lithium compound, a lithium salt, lithium carbonate, a polymeric salt of lithium, a mixture of lithium carbonate with a polymeric salt of lithium, or a lithium salt of an acrylic homopolymer, an acrylic copolymer, a copolymer of acrylic acid and maleic acid and/or acrylamide, a polyphosphate, or any mixture thereof. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time da su navedeni litijevi ioni osigurani u obliku litijevog spoja topivog u vodi, poželjno u obliku litijevih soli, te su navedene litijeve soli još poželjnije odabrane od litijevog karbonata, polimernih litijevih soli i mješavina litijevog karbonata sa polimernim litijevim solima, te su navedene polimerne litijeve soli poželjno odabrane od litijevih soli akrilnih homopolimera, akrilnih kopolimera kao što su kopolimeri akrilne kiseline i maleinske kiseline i/ili akrilamid, polifosfati i njihove smjese, navedena polimerna litijeva sol je još poželjnije odabrana od Li2Na2 polifosfata, litij-natrijevog heksametafosfata ili litijevog poliakrilata, te je navedena litijeva sol najpoželjnije litijev karbonat.
a removable cap, wherein the removable cap includes a first vent configured to allow air to flow into the device, and wherein the removable cap is removable from the body to allow scented material to be installed within the first interior or within a second interior of the removable cap; and wherein the body is further arranged so as to allow air that has entered the device through the first vent to become scented and flow out of the device through a second vent included in the device, and wherein the second vent is included in the top portion of the device. 
premjestiva kapica (112), pri čemu premjestiva kapica uključuje ulazni otvor (114) koji je učinkovit za puštanje zraka da struji u uređaj, i pritom se premjestiva kapica može premjestiti u svrhu omogućavanja uvođenja aromatičnog materijala unutar prve nutrašnjosti ili unutar druge nutrašnjosti od premjestive kapice; i gdje je tijelo dodatno oblikovano tako, da zraku koji je ušao u uređaj kroz ulazni otvor, omogućava da se aromatizira i struji izvan uređaja kroz izlazni otvor (414) koji je razmaknut od ulaznog otvora na uređaju i koji je sastavni dio gornjeg odsječka ili donjeg odsječka uređaja.
The method of para 41, wherein said fermentation medium is a food product. The method of para 43, wherein said food product is a dairy product. 
Postupak prema zahtjevu 20, naznačen time da navedeni fermentacijski medij je prehrambeni proizvod kao što je mliječni proizvod, na primjer mlijeko
A kit according to claim 9, characterised in that the therapeutic component (1 b) is selected from the group consisting of a reservoir for active agent, a metallic wire and a combination thereof. 
Set prema zahtjevu 9, naznačen time što se terapijska komponenta (1b) izabire iz grupe koja obuhvaća spremnik djelatne tvari, metalnu žicu i njihovu kombinaciju.
A multicomponent microbicidal contraceptive intravaginal ringed-mesh device as in claim 5 wherein the least one bioactive agent is selected from the group consisting of metronidazole, miconazole, ketoconazole, fluconazole, tobramycin, rapamycin, amphotericin, 5-flurocytosine, ciprofloxacin, tetracycline, doxycycline, zidovudine, acyclovir, penciclovir, ganciclovir, cidofovir, lamivudine, zalcitabine, valacyclovir, stavudine, ritonavir, indinavir, didanosine, dideoxyadinosine, clotrimazole, terbinafine, chlorhexidine, mafenide, clindamycin, paclitaxel, mitomycin, 5-flurouracil, leflunomide, enfuvirtide, gemcitabine erythromycin, ofloxacin, ceftriaxone, and cerpodoxime. 
Uređaj u vidu višekomponentne mikrobicidne kontraceptivne intravaginalne prstenaste mrežice u skladu s patentnim zahtjevom 3, naznačen time što najmanje jedno bioaktivno sredstvo se bira iz skupine koju čine metronidazol, mikonazol, ketokonazol, flukonazol, tobramicin, rapamicin, amfotericin, 5-fluorcitozin, ciprofloksacin, tetraciklin, doksiciklin, zidovudin, aciklovir, penciklovir, ganciklovir, cidofovir, lamivudin, zalcitabin, valaciklovir, stavudin, ritonavir, indinavir, didanozin, dideoksiadinozin, klotrimazol, terbinafin, klorheksidin, mafenid, klindamicin, paklitaksel, mitomicin, 5-fluoruracil, leflunomid, enfuvirtid, gemcitabin, eritromicin, ofloksacin, ceftriakson, te cefpodoksim.
The dosage form of claim 3, wherein said pharmaceutically acceptable surfactant is selected from the group consisting of polyoxyethylene alkyl ethers, polyoxyethylene alkylaryl ethers, polyethylene glycol fatty acid esters, aikyiene giycoi fatty acid mono esters, sucrose fatty acid esters, sorbitan fatty acid mono esters or mixtures of one or more thereof. 
Dozirni oblik prema zahtjevu 3, gdje se farmaceutski prihvatljiv surfaktant izabire iz skupine koja obuhvaća polioksietilen etere alkila, polioksietilen etere alkilarila, polietilen glikol estere masnih kiselina, alkilen glikol monoestere masnih kiselina, saharoza esteri masnih kiselina, sorbitan esteri masnih kiselina ili smjese jednog ili više njih.
The present invention refers to a process for the resolution into one of its enantiomers of the racemate of compound of formula (I): which comprises separating said one of its enantiomers from a diastereoisomeric salt of formula (II), which is formed by reaction of the racemic mixture with an optically active acetylated amino acid of formula (III). 
Postupak razdvajanja racemata spoja formule (I) u jedan od njegovih enantiomera: naznačen time što se sastoji u izdvajanju navedenog jednog od njegovih enantiomera iz dijastereoizomerne soli formule (II): gdje je HX optički aktivna acetilirana aminokiselina formule (III): gdje: n je 0, 1, 2 ili 3, R1 je H, alkilna skupina, arilna skupina, heteroarilna skupina, CONH2, COOH, SR2 ili OR2, gdje je R2 C1-C6 alkil.
A prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression or allergic rhinitis, which comprises the phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to any one of [1] to [11] above as an active ingredient. 
Sredstvo za profilaksu ili terapeutsko sredstvo za demenciju, Alzheimerovu bolest, poremećaj hiperaktivnosti sa nedostatkom pažnje, shizofreniju, epilepsiju, konvulzije, poremećaje u prehrani, pretilost, dijabetes, hiperlipidemiju, poremećaj spavanja, narkolepsiju, sindrom apneje u snu, poremećaj dnevnog ritma, depresiju ili alergijski rinitis, naznačeno time da kao aktivnu tvar sadrži derivat fenilpirazola ili njegovu farmaceutski prihvatljivu sol prema bilo kojem zahtjevu od 1 do 11.
R2 H, alkyl such as an isobutyl group, olefinic, aromatic group such as Ph, O-alkyl, 
H, alkil kao što je izobutil skupina, olefin skupina, aromatska skupina kao što je Ph, O-alkil, Oolefinska ili O-aromatska
Also in the preferred embodiment, a fluid inlet connector 154 is provided through which fluid is provided from a supply into the housing 20, and a fluid outlet connector 156 is provided through which fluid exits the housing 20. 
Također, u ovom preferiranom rješenju postoji ulaz za tekućinu (154) kroz koje se u kućište dobavljaju tekuća sredstva iz izvora, te izlaz za tekućinu (156), kroz koji tekuća sredstva izlaze iz kućišta (20).
halogen, lower alkyl, which may have one or more hydroxy, or 
C1-6 alkil, koji može imati ili više hidroksi, ili
In particular, the element 18 comprises an upper ring section 29 and a spaced lower ring section 30 as shown in FIGS. 8 to 10 . 
Posebno, element 18 obuhvaća gornji prstenasti dio 29 i odmaknuti donji prstenasti dio 30, kao što je prikazano na slikama 8 do 10.
An optical assembly, configured to be used in a plant for storage and/or production of energy of solar origin, which optical assembly comprises: 
Optički sklop (2, 3), prikladan za upotrebu u postrojenju (1) za skladištenje i / ili proizvodnju energije sunčevog porijekla, koji obuhvaća:
the pharmaceutical composition for oral administration of [5], wherein 85% or more of solifenacin is dissolved for 30 minutes and 90% or more of solifenacin is dissolved for 60 minutes; 
Tableta za oralnu primjenu prema zahtjevu 3, gdje se 85% ili više solifenacina otpušta nakon 30 minuta i 90% ili više solifenacina se otpušta nakon 60 minuta.
The solid oral extended release pharmaceutical dosage form of anyone of items 59 to 82, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3, preferably equal to or less than about 1.19 g/cm3. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/em poželjno jednaka ili manja od oko 1.19 g/em'.
joining the first welt of the fabric strip to the open border of the knitted article, so as to obtain an assembled, one-piece knitted article. 
– spajanje prvog obruba (6) trake od tkanine (5) s otvorenim rubom (4) pletenog artikla (2), kako bi se dobilo složeni, jednodijelni pleteni artikl.
The method as in any one of the preceding embodiments, wherein the method further comprises the step of applying wear resistant particles (16), preferably aluminum oxide particles, on the paper (2) before heating the décor (8). 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja čestica koje su otporne na habanje (16), poželjno čestice aluminij oksida na papir (2) prije zagrijavanja dekora (8).
In one of the cases of the invention implementation, the daylight surface high-frequency generator of the OWT heating unit is electrically connected by a grounded wire to OWT. 
U jednom slučaju primjene izuma, generator visoke frekvencije toplinske jedinice CNL-a, koji se nalazi na površini (danjem svjetlu), električki je povezan za CNI uzemljenom žicom.